India Pharma Outlook and Latest News – Pharmaceutical Industry in India
India’s pharmaceutical industry is one of the world’s largest, ranking third globally by volume and 14th by value, with a market valued at approximately $60 billion. Known as the “Pharmacy of the World,” India provides around 40% of the generic medicines consumed in the United States and produces more than 50% of the world’s vaccines.
The Indian pharma sector is projected to grow 9–11% in FY2026, driven by strong domestic demand of 8–10% and robust European market expansion of 15–17%, while US growth slows to 4–6% due to price erosion and regulatory challenges. Operating profit margins remain stable at 24–25% supported by favorable raw material costs and rising specialty product share, with R&D spending at 6–7% of revenues focused on complex molecules and innovation. The industry is transitioning from volume-led supply to value-driven global partnerships, moving from “World’s Pharmacy” to “World’s Innovation Partner,” as exports hit a record $30+ billion in FY25 (+9.4% over FY24). With $250 billion worth of innovator drugs going off patent over the next 5 years, significant opportunities exist for generics and complex products, backed by government support of Rs. 5,268 crore for the Department of Pharmaceuticals and GST exemptions on select medicines.
India Pharma Monitor is designed as a centralized platform to track these developments efficiently. It curates key updates across regulatory changes, market trends, export activity, research advancements, and industry movements in a structured format. The aim is to offer readers a clear and reliable overview of the Indian pharmaceutical landscape, enabling quicker insights, easier comparison, and better-informed understanding of the sector.
Latest Pharma News
Follow the latest pharma news from India and the wider pharmaceutical industry. This section highlights major headlines, breaking developments, and important daily updates.
-
GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs
GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs Reuters
-
Keeping drugs free of contaminants – pharmaceutical makers filter medications through tiny pores to keep them sterile and safe
Keeping drugs free of contaminants – pharmaceutical makers filter medications through tiny pores to keep them sterile and safe Japan Today
-
Uniquity Bio Taps Jason Moore as New SVP of Regulatory & Quality
Uniquity Bio Taps Jason Moore as New SVP of Regulatory & Quality Contract Pharma
-
Ministry of Ayush Overhauls Drugs Rules, 1945: Perpetual Manufacturing Licences, Revised GMP Standards, New Inspector Qualifications and Stronger Quality Controls for ASU Drug Industry
Ministry of Ayush Overhauls Drugs Rules, 1945: Perpetual Manufacturing Licences, Revised GMP Standards, New Inspector Qualifications and Stronger Quality Controls for ASU Drug Industry drugscontrol.org
-
Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%
Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40% Business Standard
Regulatory Updates
Track pharmaceutical regulatory updates, policy changes, and compliance-related news. This section is useful for staying informed about approvals, guidelines, and official announcements.
-
Lupin gets FDA approval for Diazepam Injection, USP
Lupin gets FDA approval for Diazepam Injection, USP Chain Drug Review
-
How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval
How 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval Fierce Pharma
-
PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent Protecting HemiClor® Formulation Technology
PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent Protecting HemiClor® Formulation Technology BioSpace
-
Alembic Pharma gets U.S. FDA nod for generic chronic constipation drug
Alembic Pharma gets U.S. FDA nod for generic chronic constipation drug The Hindu
-
NanoViricides Seeks Regulatory Approval for Ebola Trial of NV-387 Oral Gummies in DRC
NanoViricides Seeks Regulatory Approval for Ebola Trial of NV-387 Oral Gummies in DRC citybuzz -
Drug Approvals
Read about new drug approvals, product clearances, and important authorisations. This section covers medicines entering the market and other notable approval milestones.
-
NUZOLVENCE® Approved in Thailand for Gonorrhoea
NUZOLVENCE® Approved in Thailand for Gonorrhoea TheReporterAsia
-
Regulatory tracker: MannKind gets FDA nod for speedy edema autoinjector
Regulatory tracker: MannKind gets FDA nod for speedy edema autoinjector Fierce Pharma
-
Co Kilkenny woman diagnosed with rare disease sues HSE over access to drug
Co Kilkenny woman diagnosed with rare disease sues HSE over access to drug BreakingNews.ie
-
‘Irreversible consequences’ – woman with Friedreich’s ataxia sues HSE over alleged delays in application determination
‘Irreversible consequences’ – woman with Friedreich’s ataxia sues HSE over alleged delays in application determination Irish Independent
-
Woman, 28, with rare disease Friedreich's ataxia sues HSE over access to drug
Woman, 28, with rare disease Friedreich's ataxia sues HSE over access to drug Irish Examiner
Clinical and Research Updates
Explore clinical trial news, research findings, and developments in pharmaceutical science. This section focuses on innovation, studies, and progress in drug development.
-
Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol-Use Disorder Trial
Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol-Use Disorder Trial MedCity News
-
Overheard in Medicine: Betting on Clinical Trials?
Overheard in Medicine: Betting on Clinical Trials? Medscape
-
Simtriyo (Centanafadine) for ADHD: How It Works and Side Effects
Simtriyo (Centanafadine) for ADHD: How It Works and Side Effects Everyday Health
-
Topline results from LiBBY trial show THC/CBD combination significantly reduces agitation for people with dementia at end of life
Topline results from LiBBY trial show THC/CBD combination significantly reduces agitation for people with dementia at end of life EurekAlert!
-
CBD and THC Reduce Dementia Agitation
CBD and THC Reduce Dementia Agitation Neuroscience News
Industry Events
Discover pharma conferences, exhibitions, seminars, and industry events in India. This section helps readers keep track of sector gatherings and professional events.
-
New Study Shows Mail-Order Satisfaction Rising as Retail Trust Slips
New Study Shows Mail-Order Satisfaction Rising as Retail Trust Slips Drug Topics
-
The City Quantum & AI Summit to Examine How Industries Can Work Together as Quantum Computing and AI Advance
The City Quantum & AI Summit to Examine How Industries Can Work Together as Quantum Computing and AI Advance The Quantum Insider
-
Trevi's CEO and CFO join August biotech events in two states
Trevi's CEO and CFO join August biotech events in two states Stock Titan
-
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 Yahoo Finance
-
Global Mental Health, Psychiatry & Wellness Summit 2026
Global Mental Health, Psychiatry & Wellness Summit 2026 Jefferson Public Radio
Company Announcements
View company announcements including results, partnerships, expansions, and strategic updates. This section offers insights into the latest moves by pharma businesses.
-
NILA Set for First U.S.-Licensed Exchange Availability Aug. 3
NILA Set for First U.S.-Licensed Exchange Availability Aug. 3 Stock Titan
-
MindWave Innovations Launches MindChain, the First Fully Insured Blockchain, and Lists NILA Token on U.S. Exchange
MindWave Innovations Launches MindChain, the First Fully Insured Blockchain, and Lists NILA Token on U.S. Exchange citybuzz -
Market and Sector Headlines
Stay informed on market trends, sector performance, and broader industry headlines. This section gives a wider view of the forces shaping the pharmaceutical market.
-
Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?
Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape? simplywall.st
-
BDR Pharmaceuticals eyes controlling stake in Acme Formulation
BDR Pharmaceuticals eyes controlling stake in Acme Formulation The Economic Times
-
Do Chugai Pharmaceutical's (TSE:4519) Stronger EPS Trends Signal a Shift in Its Profit Model?
Do Chugai Pharmaceutical's (TSE:4519) Stronger EPS Trends Signal a Shift in Its Profit Model? simplywall.st
-
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs The Motley Fool
-
GSK Stock Jumps As 3 Biotech Names Gain From Its R And D Reset
GSK Stock Jumps As 3 Biotech Names Gain From Its R And D Reset simplywall.st
Policy and Government Initiatives
This section covers new regulations, industry support measures, and reforms that affect manufacturing, pricing, and compliance. It is also useful for following government schemes that encourage domestic production, exports, and research-led growth.
-
ONGC okays $500 million guarantee for MRPL to import oil from Aramco
ONGC okays $500 million guarantee for MRPL to import oil from Aramco Business Standard
-
BDR Pharmaceuticals eyes controlling stake in Acme Formulation
BDR Pharmaceuticals eyes controlling stake in Acme Formulation The Economic Times
-
Net FDI decline due to increased repatriation by foreign investors: Govt
Net FDI decline due to increased repatriation by foreign investors: Govt Business Standard
-
The reform booster shot that transformed India into pharmacy of the world
The reform booster shot that transformed India into pharmacy of the world Business Standard
-
Govt says EV policy goes beyond incentives, targets manufacturing and technology adoption
Govt says EV policy goes beyond incentives, targets manufacturing and technology adoption ET Auto
Get the top pharma headlines every morning
One short email a day with the biggest stories in Indian and global pharma. Free, and you can unsubscribe any time.